ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
November 27, 2023 16:30 ET
|
ACELYRIN, INC.
LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines...
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
November 07, 2023 16:05 ET
|
ACELYRIN, INC.
Portfolio of programs continues to advance with data from both the global Phase 2b/3 trial for izokibep in PsA and proof-of-concept for lonigutamab as a subcutaneous treatment for thyroid eye disease...
ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer
November 06, 2023 07:00 ET
|
Acelyrin, Inc.
Expands capacity for multi-asset manufacturing with highly accomplished supply chain, manufacturing and quality control leader bringing more than 25 years of biopharmaceutical experience across...
ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023
October 31, 2023 16:30 ET
|
Acelyrin, Inc.
LOS ANGELES, Oct. 31, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines...
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development
October 03, 2023 07:00 ET
|
Acelyrin, Inc.
Veteran drug developer and prior CMO from Novartis AG gene therapies brings decades of clinical experience including long tenure as Global Lead for secukinumab, which he advanced from early...
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
September 11, 2023 16:05 ET
|
Acelyrin, Inc.
The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis. HiSCR75 did meet statistical significance at week 16 in a Last...
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023 07:00 ET
|
Acelyrin, Inc.
LOS ANGELES, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage biopharma company focused on accelerating the development and delivery of transformative medicines in...
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
August 14, 2023 16:05 ET
|
Acelyrin, Inc.
New data from Part A of Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa demonstrated improvements in number of draining tunnels in two-thirds of patients as early as week 4; the...
ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023
August 07, 2023 16:30 ET
|
Acelyrin, Inc.
LOS ANGELES, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines...
ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer
July 18, 2023 07:00 ET
|
Acelyrin, Inc.
Accomplished global leader brings 20 years of immunology sales and marketing expertise. ACEYLRIN currently has a robust portfolio including late-stage clinical trials underway supporting multiple...